Posted by Michael Wonder on 14 May 2021
Vaccine patent waivers deserve a warning label
13 May 2021 - The move to suspend patents on COVID-19 vaccines opens up a major risk to the way the drug industry does business.
The decision by the Biden administration to support a temporary waiver on patents for COVID-19 vaccines might not end up costing the drug industry a dime, but investors who make that assumption are playing a dangerous game.
It remains uncertain whether the World Trade Organization will approve the vaccine waiver, not least because the European Union has been cool to the idea.
